Belgian Metals and Mining Stock News

argenx (ENXTBR:ARGX) is back on investor radars after the FDA expanded the labels for Vyvgart and Vyvgart Hytrulo to cover all serotypes of adult generalized myasthenia gravis, significantly widening eligible patient coverage. See our latest analysis for argenx. The FDA label expansion lands after a busy stretch for argenx, including strong Q1 2026 results with higher Vyvgart sales, a CEO transition to Karen Massey, and a 1 year total shareholder return of 35.24%. However, the year to date...

Recent returns and what they might mean for investors KBC Ancora (ENXTBR:KBCA) has quietly posted mixed share price moves, with a 0.6% decline over the past day, a 2.2% gain over the past week, and around 4.5% over the past month. For longer term holders, the stock shows a modest gain of about 0.3% over the past 3 months, alongside a year to date return of roughly 5.4% and a 1 year total return close to 38.3%. See our latest analysis for KBC Ancora. With the share price at €79.4, KBC Ancora...

In April 2026, Melexis NV reported first quarter sales of €202.09 million, modestly above a year earlier, while net income eased to €23.09 million and basic EPS from continuing operations slipped to €0.57. At the same time, the company confirmed its 2026 guidance, expecting first half sales to be broadly unchanged year over year with an operating margin around 17% and indicating that second half sales should exceed the first half. We’ll now examine how Melexis’ confirmed first half operating...

Solvay stock moves after recent performance data Solvay (ENXTBR:SOLB) has come into focus after a period in which the stock showed negative returns over the past month and past 3 months, prompting closer attention to its fundamentals and profitability profile. See our latest analysis for Solvay. At a share price of €26.28, Solvay’s recent 7 day share price return of a 5.81% decline adds to a year to date share price return of a 3.88% decline, contrasting with a 42.41% three year total...

argenx (ENXTBR:ARGX) appointed Karen Massey as CEO, and co founder Tim Van Hauwermeiren moved to Chairperson. The company reported strong Q1 results, with accelerating VYVGART sales highlighted as a key driver. An FDA decision on a potential Vyvgart label expansion in seronegative generalized myasthenia gravis is expected soon. argenx focuses on antibody based therapies for autoimmune diseases, with VYVGART already a central product in its portfolio. For investors watching the immunology...

What the latest guidance and results mean for Melexis (ENXTBR:MELE) Melexis (ENXTBR:MELE) shares have been reacting to the company confirming its 2026 guidance alongside Q1 results, with sales at €202.09 million and net income at €23.09 million, compared with €24.6 million a year earlier. See our latest analysis for Melexis. The confirmation of 2026 guidance alongside Q1 results appears to have shifted sentiment, with the stock’s 30 day share price return of 39.34% and 1 year total...

Anheuser-Busch InBev (ENXTBR:ABI) has been named the 2026 Creative Marketer of the Year by the Cannes Lions International Festival of Creativity. This is the first time any company has received the award three times. The recognition follows the company winning 37 Lions at last year's festival. Anheuser-Busch InBev, the global brewer behind brands across beer and beyond, is being recognized for how it uses marketing and creativity across its portfolio. For investors, this award signals that...

Syensqo cancelled a significant number of shares it had repurchased as part of its ongoing buyback program. The move changes the total number of outstanding shares and voting rights for ENXTBR:SYENS. The action forms part of a broader capital management approach that affects how ownership is distributed across shareholders. For investors watching ENXTBR:SYENS, the cancellation of repurchased shares directly alters the share count that sits behind the current €57.3 price. Recent performance...

If you are wondering whether Umicore’s recent share price movement makes the stock look expensive or if there is still value available, this article breaks down what the current price might be implying. The share price closed at €21.82, with returns of 27.0% over 7 days, 23.6% over 30 days, 17.4% year to date, 167.3% over 1 year, a 17.3% decline over 3 years, and a 51.2% decline over 5 years. This gives you a mixed picture depending on your time frame. Recent coverage has focused on...

argenx (ENXTBR:ARGX) has opened 2026 with Q1 revenue of about US$1.3b and basic EPS of US$5.90. On a trailing 12 month basis the company has generated US$4.7b of revenue and basic EPS of US$24.19. This sets a clear earnings backdrop for investors watching the stock around its current US$671.20 share price. Over recent quarters the company has seen revenue move from US$807.37m in Q1 2025 to roughly US$1.3b in Q1 2026, with quarterly basic EPS ranging between US$2.78 and US$12.79 across that...

As you might know, Anheuser-Busch InBev SA/NV ( EBR:ABI ) just kicked off its latest first-quarter results with some...

Solvay (ENXTBR:SOLB) opened 2026 with Q1 revenue of €1.1 billion and basic EPS of €0.25, alongside trailing twelve month revenue of €4.6 billion and a basic EPS loss of €0.24, setting a mixed backdrop for the latest results. Over recent quarters the company has seen revenue range between €1.1 billion and €1.3 billion per quarter, with basic EPS moving from €0.78 in Q1 2025 through several smaller profits and a loss of €0.90 in Q4 2025 before rebounding in Q1 2026, leaving investors focused on...

Anheuser-Busch InBev (ENXTBR:ABI) opened 2026 with Q1 revenue of US$15.3b and basic EPS of US$1.30, setting a clear benchmark for how the rest of the year might shape up for the brewer’s top and bottom lines. The company has seen quarterly revenue move from US$13.6b in Q1 2025 to US$15.3b in Q1 2026, while basic EPS shifted from US$1.08 to US$1.30 over the same period. This gives you a clean read on how sales and per share earnings are tracking through the cycle. With that backdrop, the...

Earnings snapshot and why it matters now Cofinimmo (ENXTBR:COFB) has just reported first quarter 2026 results, with sales of €87.31 million compared with €86.81 million a year earlier, while net income came in at €53.51 million versus €64.26 million. This mix of slightly higher sales and lower profitability is giving investors fresh numbers to reassess the stock, especially following the recent share price moves over the past month and over the past three months. See our latest analysis for...

Executive and board reshuffle puts Umicore (ENXTBR:UMI) in focus Umicore (ENXTBR:UMI) has drawn fresh attention after shareholders approved new Supervisory Board appointments, while the company also named a new CFO and created a Chief Digital & Transformation Officer role. See our latest analysis for Umicore. The cluster of governance changes, dividend approval and BlackRock lifting its holding above 5% has coincided with a sharp pick up in momentum, with a 24.04% 1 month share price return...

Why Anheuser-Busch InBev (ENXTBR:ABI) is Back on Investor Radar Anheuser-Busch InBev (ENXTBR:ABI) has drawn attention after its recent share performance, with the stock showing positive returns over the past week, month and past 3 months alongside measurable annual revenue and net income. See our latest analysis for Anheuser-Busch InBev. The recent 1-day share price return of 9.34% builds on a 30-day share price return of 12.26% and a year to date share price return of 26.91%. The 1-year...

Investors may be wondering whether argenx at €678.60 is offering fair value or carrying a premium, particularly after its strong long term share price record. The stock has returned 2.0% over the last 7 days, 4.9% over the last 30 days, a 6.2% decline year to date and 19.8% over the last year, with longer term returns of 86.7% over 3 years and 220.1% over 5 years. Recent coverage around argenx has focused on its position in the biotech sector and investor debate around how much future growth...

What recent performance suggests about Azelis Group (ENXTBR:AZE) Azelis Group (ENXTBR:AZE) has drawn attention after a month return of 26.0%, contrasting with a 16.7% decline over the past year. This puts its recent share move in focus for investors. See our latest analysis for Azelis Group. The recent 26.0% 30 day share price return and 24.8% 90 day gain contrast with a 16.7% 1 year total shareholder return decline, suggesting short term momentum after a weaker longer period. If this kind of...

Dividend increase puts income focus on Financière de Tubize Financière de Tubize (ENXTBR:TUB) has approved a gross dividend of €1.08 per share at its 24 April 2026 general meeting, with payment scheduled from 11 May, ex-coupon on 7 May. See our latest analysis for Financière de Tubize. The dividend decision comes after a weaker 30 day share price return of a 10.84% decline and a 12.44% decline over 90 days. However, the 1 year total shareholder return of 46.48% and 3 year total shareholder...

Why Xior’s latest quarterly results matter for investors Xior Student Housing (ENXTBR:XIOR) has drawn fresh attention after reporting first quarter 2026 earnings, with sales of €48.67 million and net income of €48.6 million, compared with €43.88 million and €41.95 million a year earlier. See our latest analysis for Xior Student Housing. Despite the stronger first quarter figures, the share price is at €27.6, with a 1 day share price return of 0.91% but a 1 year total shareholder return of...

Sofina Société Anonyme (ENXTBR:SOF) has drawn investor attention after its recent share price moves, with a gain over the past month contrasting with weaker returns in the past 3 months and year. See our latest analysis for Sofina Société Anonyme. At the latest share price of €218.0, Sofina Société Anonyme's short term share price return has been slightly positive over the past month, while the year to date share price return and 1 year total shareholder return both remain negative,...

Umicore (ENXTBR:UMI) has appointed Lily Liu as Chief Financial Officer and Executive Vice President. The company is also creating a new Chief Digital & Transformation Officer role to focus on digitalization and operational excellence. These leadership changes reflect a shift in how Umicore organizes its executive team and oversees transformation initiatives. For investors watching ENXTBR:UMI, the leadership reshuffle comes with the stock at €17.18 and a mixed return profile. The share price...

Why argenx is back in focus for investors argenx (ENXTBR:ARGX) is back on investors' radar after fresh analyst commentary highlighted expectations for its first quarter update, with particular attention on Vyvgart's prefilled syringe use in autoimmune conditions. That growing focus comes ahead of key regulatory milestones in ocular and seronegative myasthenia gravis. Upcoming decisions could influence how investors think about argenx's longer term growth runway and risk profile. See our...

NICE’s green light for UCB (ENXTBR:UCB) therapy Rystiggo for uncontrolled generalised myasthenia gravis on the NHS in England, plus the IMIDomics Patient Insight acquisition, has sharpened investor focus on the stock. See our latest analysis for UCB. The 1 day share price return of 2.21% takes UCB to €231.2, yet this comes after a 30 day share price return of negative 12.59%. This is even as the 1 year total shareholder return of 36.64% and 5 year total shareholder return of 211.86% point to...